BioGaia AB (publ) (BIOG_B) Q1 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Biogaia Ab Class B.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:01.317 -- 00:00:06.419 Hi, this is Teresa Agnew, CEO of BioGaia, and I'm here with Alexander Koutsinas, 00:00:06.419 -- 00:00:08.340 our CFO. 00:00:08.340 -- 00:00:10.961 So we are here to report on our Q1 2025 results. 00:00:10.961 -- 00:00:15.302 For Q1, our sales were $366 million sec, which was 00:00:17.802 -- 00:00:22.345 a decrease of 1%, so relatively flat to last year. 00:00:22.345 -- 00:00:27.389 This was mainly due to lower sales in Asia Pacific and as well as Europe, Middle East, 00:00:27.389 -- 00:00:33.594 Africa. Specifically in Europe, Middle East, Africa, our sales decreased by 23%. 00:00:33.594 -- 00:00:38.778 And this was mainly in France, Central Eastern Europe, and South Africa. 00:00:38.778 -- 00:00:44.022 We did see a nice increase in certain markets, such as Italy, 00:00:44.022 -- 00:00:50.098 where we are returning to growth. In Asia Pacific, we saw a decrease of 19%, 00:00:50.098 -- 00:00:56.000 and this was mainly in China, and it was also due to some order fluctuations 00:00:56.000 -- 00:01:00.841 where we had significant orders in Q4, 00:01:00.841 -- 00:01:05.161 while the Americas increased significantly by 42%. 00:01:05.161 -- 00:01:10.905 We saw strong growth in the US that was fueled by additional 00:01:10.905 -- 00:01:13.687 marketing investments that we've been doing. 00:01:13.687 -- 00:01:17.170 We also saw strong growth in Canada, 00:01:17.170 -- 00:01:19.412 as well as in Brazil. 00:01:19.412 -- 00:01:21.613 Our EBIT was 97 00:01:21.613 -- 00:01:26.546 million sec, which was a decline of 32%, and our EBIT margin was 37%. 00:01:28.915 -- 00:01:33.977 We did have some launches. What we always like to report is when we launch our 00:01:33.977 -- 00:01:40.439 products into new markets. So you see here a number of launches...